Addex Therapeutics Files 6-K, Incorporates Press Release
Ticker: ADXN · Form: 6-K · Filed: Apr 3, 2024 · CIK: 1574232
Sentiment: neutral
Topics: press-release, filing-update, sec-filing
TL;DR
Addex Therapeutics dropped a new press release on 4/3/24, check the 6-K for details.
AI Summary
On April 3, 2024, Addex Therapeutics Ltd. announced the issuance of a press release. This press release is incorporated by reference into their Form 6-K filing with the SEC. The filing also references their registration statements on Form F-3 (Registration No. 333-255089) and Form S-8 (Registration No. 333-255124 and No. 333-27).
Why It Matters
This filing indicates that Addex Therapeutics has issued a new press release, which may contain important updates regarding their business or financial status that investors should be aware of.
Risk Assessment
Risk Level: low — This filing is primarily procedural, incorporating a previously issued press release and referencing existing registration statements, with no new material financial events disclosed.
Key Players & Entities
- Addex Therapeutics Ltd. (company) — Registrant
- April 3, 2024 (date) — Date of press release and filing
- 333-255089 (registration_number) — Form F-3 registration number
- 333-255124 (registration_number) — Form S-8 registration number
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report a press release issued by Addex Therapeutics Ltd. on April 3, 2024, and to incorporate it by reference into the filing.
What exhibit is incorporated by reference into this Form 6-K?
Exhibit 99.1, a press release dated April 3, 2024, is incorporated by reference.
Which registration statements are mentioned in the filing?
The filing mentions registration statements on Form F-3 (Registration No. 333-255089) and Form S-8 (Registration No. 333-255124 and No. 333-27).
What is the company's principal executive office address?
The company's principal executive office is located at Chemin des Mines 9, CH-1202 Geneva, Switzerland.
Does Addex Therapeutics file annual reports under Form 20-F or 40-F?
Addex Therapeutics indicates that it files annual reports under Form 20-F.
Filing Stats: 272 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-04-03 06:05:07
Filing Documents
- f6k_040324.htm (6-K) — 7KB
- exh_991.htm (EX-99.1) — 11KB
- 0001171843-24-001785.txt ( ) — 19KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] On April 3, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. (c) Exhibit 99.1. Press release dated April 3, 2024 INCORPORATION BY REFERENCE Exhibits 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) of Addex Therapeutics Ltd and the registration statement on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Addex Therapeutics Ltd (Registrant) Date: April 3, 2024 /s/ Tim Dyer Tim Dyer Chief Executive Officer EXHIBIT INDEX Exhibit Number Description 99.1 Press release dated April 3, 2024